Short answer
Anika Therapeutics, Inc. (ANIK) filed an 8-K current report with the SEC on July 14, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). $50.0M senior revolving credit facility extended through July 10, 2031.
Anika Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $50.0M senior revolving credit facility extended through July 10, 2031
- Potential $50.0M expansion, bringing maximum commitments to $100.0M subject to lender approval
- Borrowing cost: SOFR plus 0.25%–1.25%, tied to consolidated leverage
- Financial covenants cap leverage and require minimum interest coverage, constraining borrowing flexibility
- First-priority liens cover substantially all assets except certain intangible assets, increasing lender protections
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Anika Therapeutics, Inc. 8-K filings
Get the next ANIK 8-K as it lands
Follow ANIK for push alerts, or ask the research agent what this filing means.